ClinicalTrials.gg
RecruitingNCT07730294Updated Nov 6, 2026

Evaluating Intranasal Oxytocin (TNX-1900) for Pain Relief and Recovery After Pituitary Surgery

A Phase 2 interventional study of Oxytocin (Low dose) and Oxytocin (High dose) in Pain and Pituitary Surgery, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know

Updated Nov 6, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Pain by Yale University — 8 open to participants now, 8 under way, none of them phase 3. Pain · Yale University.

Planned enrollment
8th of 29
75 · median 27
Started
2026
with 1 other
Phase 2
5 of 30
2 open now
Registered
29th of 30
by date

Among the 30 studies in Pain by Yale University, this one is the 8th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 2, and was the 29th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

8 of the 30 studies in Pain by Yale University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Pain by Yale University, or all of them as a file.
02

Study summary

This study is testing whether oxytocin can help lessen pain by changing how people process emotions and social experiences. The goal is to better understand how the brain links emotions, relationships, and pain, and whether this connection can be used to improve pain treatment.

Read the detailed description

This study employs a randomized, double-blind, placebo-controlled design to evaluate the efficacy of an intranasal oxytocin formulation, TNX-1900, on pain management, neural functioning, and socio-emotional health in patients undergoing pituitary surgery. Participants will be randomized into 3 groups: One group will receive low-dose oxytocin (6 IU), one group will receive high-dose oxytocin (24 IU), and one group will receive a matching placebo formulation. Participants will administer their nasal spray (blinded) daily for 7 days leading up to, and including the day of surgery, and 7 days following the surgery. Assessments (surveys and EEG/ERP) will be included throughout the protocol.

03

Conditions studied

  • Pain
  • Pituitary Surgery

Browse trials for

Keywords

  • pain
  • pain perception
  • oxytocin
  • intranasal
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Between 30 to 75 years old.
  • Consent: Ability to give .
  • Language: Proficiency in the English language.
  • Medical Condition: Diagnosed with a pituitary lesion requiring surgery.
  • Menopausal Status: for women (at least 1 year since last menstrual period).

Exclusion criteria

Exclusion Criteria:

  • Medication: Individuals on stable doses of psychotropic medication for at least the past six weeks are eligible, excluding those with changes in medication within that timeframe.
  • Neurological Conditions: A history of seizures, current use of anticonvulsants.
  • Pregnancy: Currently pregnant, currently lactating, or up to 1-year post partum.
  • Any history of renal impairment (serum creatinine >1.2 x )
  • Any history of hepatic impairment ( and/or ALT >2 x ULN)
  • Surgical History: Any history of previous pituitary surgery procedures
  • Subjects who require 24-hour coverage with NSAIDs, e.g., arthritis, should not be included in the study.
  • Any known to TNX-1900
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Low Dose Oxytocin

    Participants in this arm will receive low dose oxytocin beginning one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.

    Drug: Oxytocin (Low dose)

  • Experimental
    High Dose Oxytocin

    Participants in this arm will receive high dose oxytocin beginning one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.

    Drug: Oxytocin (High dose)

  • Placebo comparator
    Saline-Mg solution

    Participants in this arm will receive placebo beginning one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.

    Drug: Placebo (saline)

Interventions

  • DrugOxytocinStudies of OxytocinOxytocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The dosage for low -dose intranasal oxytocin is set at 6 International Units (IU) per day, divided into two administrations of 3IU each per nostril. The administration begins one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.

  • DrugOxytocinStudies of OxytocinOxytocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The dosage for high-dose intranasal oxytocin is set at 24 International Units (IU) per day, divided into two administrations of 12 IU each per nostril. The administration begins one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.

  • DrugPlacebo (saline)

    Placebo nasal spray (no study medication, magnesium only). The administration begins one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.

06

What researchers measure

Primary outcomes

  1. Change in post-operative pain measured by the Numeric Pain Rating Scale (NPRS)

    The NPRS is a patient-reported tool used to assess pain intensity on a scale from 0 (no pain) to 10 (worst possible pain).

    Time frame: Pre-op up to 8 weeks after last drug administration

  2. Change in post-operative pain measured by monitoring of pain medication usage

    Daily pain medication usage will be reported by participants leading up to surgery and after discharge. Daily pain medication usage will be reported through the participant's medical record during surgery and inpatient stay.

    Time frame: Pre-op up to 8 weeks after last drug administration

Secondary outcomes

  1. Changes in participant reported depression as measured by the Beck Depression Inventory (BDI-II)

    BDI-II is a 21-item patient-reported questionnaire used to assess the severity of depressive symptoms. Total scores range from 0 to 63, with higher scores indicating more severe depression.

    Time frame: Pre-op up to 8 weeks after last drug administration

  2. Changes in participant reported anxiety as measured by the Beck Anxiety Inventory (BAI)

    BAI is a 21-item patient-reported questionnaire used to assess the severity of anxiety symptoms. Total scores range from 0 to 63, with higher scores indicating more severe anxiety.

    Time frame: Pre-op up to 8 weeks after last drug administration

  3. Changes in participant reported anxiety as measured by the Generalized Anxiety Disorder-7

    GAD-7 is a 7-item patient-reported questionnaire used to assess the severity of anxiety symptoms. Total scores range from 0 to 21, with higher scores indicating more severe anxiety.

    Time frame: Pre-op up to 8 weeks after last drug administration

  4. Changes in participant reported depression as measured by the Patient Health Questionnaire-9

    PHQ-9 is a 9-item patient-reported questionnaire used to assess the severity of depressive symptoms. Total scores range from 0 to 27, with higher scores indicating more severe depression.

    Time frame: Pre-op up to 8 weeks after last drug administration

  5. Change in neural functioning measured by Electroencephalography (EEG)/Event-Related Potential (ERP)

    EEG/ERP sessions are done at specific intervals to look at delta-beta neural oscillations and N170, P300, and LPP ERPs elicited by social and emotional stimuli (photos of faces and houses).

    Time frame: Pre-op and the last day of drug administration, approximately 14 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share Individual Participant Data at this time.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 125 non-industry phase 2 interventional studies under Pain, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's planned 24 months is below that.

Counting every sponsor, half of 187 studies reached it within 21 months; a quarter within 8 and three quarters within 40.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, last on Nov 6, 2026.

Primary completion moved twice since we started tracking on Sep 25, 2026: Aug 2028 → Nov 2028, last on Nov 6, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Aug 2028 → Nov 2028, last on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 28, 2026
StartEst.
Nov 2026was Aug 2026
Primary completionEst.
Nov 2028was Aug 2028
CompletionEst.
Nov 2028was Aug 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
Yale University is now Recruiting
Nov 6, 2026
Start date
Aug 2026→Nov 2026
moved 2 times, Oct 21, 2026 – Nov 6, 2026
Primary completion
Aug 2028→Nov 2028
moved 2 times, Oct 21, 2026 – Nov 6, 2026
Study completion
Aug 2028→Nov 2028
moved 2 times, Oct 21, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    Yale University is now Recruiting
    Start date Oct 2026→Nov 2026
    Primary completion Oct 2028→Nov 2028
    Study completion Oct 2028→Nov 2028
    + 1 other change: verification date
  2. Oct 21, 2026
    Start date Aug 2026→Oct 2026
    Primary completion Aug 2028→Oct 2028
    Study completion Aug 2028→Oct 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07730294
Lead sponsor
Yale University
Responsible party
Sacit Omay (Associate Professor of Neurosurgery and Otolaryngology, Yale University) — Principal investigator
First posted
Jul 28, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

S. Bulent Omay, MD
Contact
sacit.omay@yale.edu
203-737-6885
Helena Rutherford, PhD
Contact
helena.rutherford@yale.edu
S. Bulent Omay, MD
principal investigator · Yale University
Helena Rutherford, PhD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxytocin

Start the discussion